ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
69 announcements with these filters
Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
Biocon's board recorded the resignation of Chief Technology Officer Mandar Ghatnekar, effective 31 December 2026. Mukesh Rathi is appointed CTO, effective 1 January 2027.
Biocon Limited informed the Exchange of shareholder communications regarding the withholding of FY 2025-26 final dividends for missing mandatory KYC and bank details.
Q2 FY27 revenue from operations ₹4,389 Cr (+2% YoY), EBITDA ₹865 Cr (20% margin vs 22%), reported PAT ₹41 Cr (−52% YoY). Management expects a stronger H2.
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.
Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.
Biocon Limited announced the re-appointment of Director Eric Vivek Mazumdar, retirement of Director Nicholas Robert Haggar, and appointment of S.R. Batliboi & Associates as new statutory auditors.
Biocon Limited held its 48th Annual General Meeting on August 06, 2026. The meeting transacted key business including adoption of financial statements and declaration of final dividend.
Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.
Biocon Ltd filed its Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its previous QIP.
Biocon reported Q1 FY27 consolidated total income of Rs 4,391 crore and a net profit of Rs 141 crore. The release highlights growth across key business segments.
Biocon Ltd reported revenue from operations of ₹4,336 Cr (+10.0% YoY) and net profit of ₹136.8 Cr (+53.4% YoY) for Q1 FY27.
Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.
Biocon received Health Canada approval for its Yesintek (ustekinumab) Autoinjector Pen. This new product format expands the company's immunology portfolio in Canada.
Biocon scheduled a board meeting for August 05, 2026, to approve the financial results for the quarter ended June 30, 2026. An earnings call follows.
Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale on July 14, 2026.
Biocon Limited announced that Independent Director Mr. Bobby Kanubhai Parikh has ceased to be a Director following the completion of his second tenure.